Skip to main content

HER2 clinical trials at UCSF

41 in progress, 15 open to eligible people

HER2 is a protein that plays a role in some types of cancer. UCSF is conducting a study involving Disitamab Vedotin for patients with bladder cancer. There is research with Elacestrant versus standard therapy for breast cancer. Another trial examines T-DM1 combined with Tucatinib to prevent breast cancer recurrence.

Showing trials for

Our lead scientists for HER2 research studies include .

Last updated: